August, 2004
No. 89 (8)

Editorials

Articles

No increase in age-specific incidence of myelodysplastic syndromes

U Germing, C Strupp, A Kundgen, D Bowen, C Aul, R Haas, N Gattermann

https://doi.org/10.3324/%25x

KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication

A Beghini, CB Ripamonti, R Cairoli, G Cazzaniga, P Colapietro, F Elice, G Nadali, G Grillo, OA Haas, A Biondi, E Morra, L Larizza

https://doi.org/10.3324/%25x

Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia

E Barragan, J Cervera, P Bolufer, S Ballester, G Martin, P Fernandez, R Collado, MJ Sayas, MA Sanz

https://doi.org/10.3324/%25x

Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia

A Venditti, G Del Poeta, L Maurillo, F Buccisano, MI Del Principe, C Mazzone, A Tamburini, C Cox, P Panetta, B Neri, L Ottaviani, S Amadori

https://doi.org/10.3324/%25x

Leukocyte-specific phosphoprotein-1 and PU.1: two useful markers for distinguishing T-cell-rich B-cell lymphoma from lymphocyte-predominant Hodgkin's disease

T Marafioti, C Mancini, S Ascani, E Sabattini, PL Zinzani, M Pozzobon, K Pulford, B Falini, ES Jaffe, HK Muller-Hermelink, DY Mason, SA Pileri

https://doi.org/10.3324/%25x

Letters to the Editor

Genetic studies suggest a novel Portuguese origin for hemoglobin Porto Alegre

P Faustino, A Miranda, I Picanco, EM Kimura, F Ferreira Costa, M de Fatima Sonati

https://doi.org/10.3324/%25x

Lack of mutations in the human telomerase RNA component (hTERC) gene in Fanconi's anemia

RT Calado, MC Pintao, V Rocha, RP Falcao, MA Bitencourt, WA Silva, E Gluckman, R Pasquini, MA Zago

https://doi.org/10.3324/%25x

Acquired angioedema: a new target for rituximab?

PD Ziakas, S Giannouli, E Psimenou, K Evangelia, AG Tzioufas, M Voulgarelis

https://doi.org/10.3324/%25x

Case Reports

Type I CD36 deficiency in hematologic disorder

Y Aota, M Sumi, T Iguchi, S Okabe, A Gotoh, K Ohyashiki

https://doi.org/10.3324/%25x

Clinical Trial

Clinical Trial, Phase II

Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups

S Amadori, S Suciu, R Willemze, F Mandelli, D Selleslag, R Stauder, A Ho, C Denzlinger, G Leone, P Fabris, P Muus, M Vignetti, A Hagemeijer, F Beeldens, O Anak, T De Witte, EORTC leukemia group, GIMEMA leukemia group

https://doi.org/10.3324/%25x

Controlled Clinical Trial

Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy

S Brunet, J Esteve, J Berlanga, JM Ribera, J Bueno, JM Marti, J Bargay, R Guardia, A Julia, A Granena, E Montserrat, J Sierra, Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias

https://doi.org/10.3324/%25x

Clinical Trial, Phase III

Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi

F Merli, M Bertini, S Luminari, R Mozzana, R Berte, M Trottini, C Stelitano, B Botto, M Pizzuti, G Quintana, A De Paoli, M Federico, Intergruppo Italiano Linfomi

https://doi.org/10.3324/%25x